Book a blood-based liquid biopsy for lung cancer mutation testing, or get a second opinion on a report you already have.
Liquid biopsy for lung cancer is a blood-based ctDNA test used in diagnosed non-small cell lung cancer (NSCLC) to detect actionable mutations such as EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, and BRAF, and to check for resistance markers when a tissue biopsy is not possible or treatment has stopped working.
Liquid Biopsy Test for Lung Cancer
Book a blood-based liquid biopsy for lung cancer mutation testing, or get a second opinion on a report you already have.
Liquid biopsy for lung cancer is a blood-based ctDNA test used in diagnosed non-small cell lung cancer (NSCLC) to detect actionable mutations such as EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, and BRAF, and to check for resistance markers when a tissue biopsy is not possible or treatment has stopped working.
500+
Genes Analyzed
24hr
Expert Callback
95%
Clinical Actionability
What Is a Liquid Biopsy for Lung Cancer?
A liquid biopsy for lung cancer is a blood test that analyzes circulating tumor DNA (ctDNA) — tiny fragments of tumor DNA shed into the bloodstream — to look for lung cancer mutations. It is used mainly in non-small cell lung cancer (NSCLC), most often in advanced or metastatic disease, to identify actionable mutations that guide targeted therapy without requiring a fresh tissue sample.
Liquid biopsy for lung cancer is well established for molecular profiling in diagnosed, advanced NSCLC — especially when tissue is unavailable, a repeat biopsy is risky, or treatment has stopped working and a resistance mutation needs to be identified quickly. It is not yet a standard screening tool for detecting lung cancer early in people without a diagnosis: current liquid biopsy assays still lack the sensitivity to reliably catch early-stage lung tumors, which shed very little ctDNA, so research in this area (early detection and screening) is active but still investigational.
Quick Facts
Blood Draw
Sample Needed
7–14 Days
Report Time
Advanced NSCLC
Best Use
Molecular Oncology Team
Reviewed By
What Liquid Biopsy for Lung Cancer Can Detect
A single panel screens for every major class of cancer-driving genetic alteration.
Actionable Lung Cancer Mutations
EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, BRAF, HER2/ERBB2 and other therapy-linked alterations in NSCLC
Resistance Mutations
EGFR T790M/C797S and other secondary mutations that explain progression on targeted therapy
ctDNA Fraction
The amount of tumor-derived DNA detected in blood, used to judge whether a negative result is reliable
MSI / TMB Signals
Selected platforms report MSI-H or blood TMB, which may support immunotherapy discussions in NSCLC
Book Lung Cancer Liquid Biopsy — Get Your Report in 7–14 Days
Blood-based lung cancer mutation profiling with expert report interpretation.
Confidential • No obligation • Expert callback within 24 hours
Why Liquid Biopsy for Lung Cancer Matters
In advanced NSCLC, a blood-based ctDNA test can give your oncologist a fast molecular readout when tissue is hard to obtain, or when treatment has stopped working and a resistance mutation needs to be found quickly.
1
blood draw instead of a repeat lung biopsy
7–14
business days for most lung cancer ctDNA reports
6+
actionable NSCLC genes commonly covered (EGFR, ALK, ROS1, KRAS, MET, RET)
Avoid a risky repeat lung biopsy
Lung tissue biopsies (bronchoscopy, CT-guided needle biopsy) carry procedural risks such as pneumothorax or bleeding. Liquid biopsy can provide molecular information from a simple blood draw instead.
Find targetable driver mutations
Liquid biopsy can detect EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, BRAF, and HER2 alterations that determine which targeted therapy is likely to work.
Understand why treatment stopped working
After progression on an EGFR or ALK inhibitor, liquid biopsy can reveal resistance mutations such as T790M or C797S that guide the next line of treatment.
Review results from any major platform
Already tested on Guardant360, FoundationOne Liquid CDx, Tempus, Caris, or a hospital ctDNA panel for your lung cancer? We can interpret the report without asking you to repeat testing unless needed.
Know the limits for early detection
If your goal is screening for lung cancer before diagnosis, be aware that liquid biopsy is not yet a validated screening tool — it is currently most reliable in diagnosed, advanced NSCLC. We can advise on appropriate options depending on your situation.
Got your report? We'll walk you through it.
Liquid Biopsy for Lung Cancer — Cost in India
Transparent lung cancer liquid biopsy pricing across India — final cost depends on platform, panel size, and whether report review is included.
Starting Prices
Compare Test Prices
Indicative starting prices for common genomics test options.
What's Included
Focused Lung Cancer ctDNA Panel
Targeted panel for EGFR, ALK, ROS1, and other common NSCLC driver and resistance mutations
upto ₹45,000
Liquid biopsy test cost for lung cancer in India varies by platform, panel size, and clinical objective — contact us for exact pricing based on your case. BigOHealth coordinates sample collection with certified labs and does not sell at-home liquid biopsy test kits — testing is arranged with clinical oversight.
Second Opinion on Your Lung Cancer Liquid Biopsy Report
If you already have a Guardant360, FoundationOne Liquid CDx, Tempus, Caris, or hospital ctDNA report for lung cancer, our molecular oncology team can review it and explain whether the findings support targeted therapy, immunotherapy, repeat tissue biopsy, or tumor board discussion.
What our experts review
Lung Cancer ctDNA Report Interpretation
We explain actionable mutations, ctDNA fraction, MSI/TMB, resistance markers, and VUS findings in clear treatment-focused language.
Platform-Specific Review
We check panel scope, detected alterations, companion diagnostic claims, and limitations for the exact report you received.
Targeted Therapy Matching
EGFR, ALK, ROS1, KRAS G12C, MET, RET, and BRAF findings are mapped to approved targeted therapies and options available in India.
Negative Report Next Steps
If no mutation was detected, we review ctDNA fraction and clinical context to decide whether tissue testing, repeat testing, or monitoring is needed.
Resistance Mutation Review
We interpret progression-related findings after EGFR or ALK inhibitor therapy, such as T790M or C797S.
Clinical Trial Eligibility
We identify whether your findings may open mutation-matched trial options or tumor board recommendations.
Why patients trust us
- Reviewed by certified molecular oncologists
- Response within 2 business hours
- 100% confidential — your data stays private
Not sure what your Liquid Biopsy for Lung Cancer report means?
What Will Your Lung Cancer Liquid Biopsy Report Say?
Most lung cancer ctDNA reports group findings into clinically actionable alterations, resistance signals, biomarker scores, ctDNA fraction, and variants that need expert interpretation.
Actionable Mutations
Mutations matched to targeted therapy options, such as EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, BRAF, or HER2.
What a Positive Result Means
A positive result identifies a specific mutation driving your lung cancer — it does not by itself tell you the stage or prognosis, which must be interpreted alongside imaging and clinical history.
TMB / MSI Signals
Selected platforms may report blood TMB or MSI status, which can contribute to immunotherapy discussions in appropriate cases.
ctDNA Fraction
The percentage or level of tumor DNA detected in blood. Low ctDNA can make a negative report less conclusive.
Resistance Mutations
Findings such as EGFR T790M/C797S may explain progression on current targeted therapy and point toward the next treatment line.
VUS
Variants of Unknown Significance are not actionable today but may be tracked over time as evidence changes.
Already have a lung cancer liquid biopsy report?
Get a second opinion to understand what a positive or negative result actually means for your treatment: which mutations matter, which findings are uncertain, and whether tissue testing or a tumor board review should come next.
Liquid Biopsy vs. Tissue Biopsy for Lung Cancer
Both approaches have a role in lung cancer. Tissue biopsy (via bronchoscopy, CT-guided needle biopsy, or EBUS) confirms diagnosis and histology; liquid biopsy adds a fast, low-risk way to profile mutations from blood.
Not sure whether you need a liquid biopsy, tissue biopsy, or both?
How Does Lung Cancer Liquid Biopsy Testing Work?
Book & Collect Sample
Our team confirms the right ctDNA panel for your NSCLC subtype and coordinates blood sample collection.
Plasma Processing
The lab separates plasma, extracts cfDNA, and performs quality checks.
Sequencing & Analysis
The selected liquid biopsy panel analyzes lung cancer genes for actionable and resistance markers.
Report Review
Your report is reviewed with molecular oncology context and next-step guidance.
Total turnaround: 7–14 business days from sample collection to final report. Our team calls back within 2 hours of your enquiry to guide you through the process.
Other Genomic Tests You May Need
Book Liquid Biopsy
General liquid biopsy testing and platform comparison
Guardant360 Test & Report Review
Book Guardant360 testing or review an existing Guardant360 report
NGS Testing
Comprehensive tissue-based genomic profiling for lung cancer
Tumor DNA Sequencing
Tissue-based somatic profiling for targeted therapy
Not sure which test applies to you?
Get a second opinion or consult our multidisciplinary tumor board to confirm the right genomic test for your diagnosis.
Liquid Biopsy for Lung Cancer Applies Across Cancer Types
NSCLC — Adenocarcinoma
The most common NSCLC subtype tested for EGFR, ALK, ROS1, KRAS G12C, MET exon 14, and RET alterations.
NSCLC — Squamous Cell
Actionable mutations are less common than in adenocarcinoma, but liquid biopsy may still be used for select cases and resistance monitoring.
NSCLC After Progression
Liquid biopsy is commonly used after progression on EGFR or ALK targeted therapy to check for resistance mutations such as T790M or C797S.
Frequently Asked Questions
Answers for both first-time patients and those who already have a Liquid Biopsy for Lung Cancer report in hand.
What is a liquid biopsy for lung cancer?
A liquid biopsy for lung cancer is a blood test that analyzes circulating tumor DNA (ctDNA) shed by lung tumors into the bloodstream. It is used mainly in diagnosed non-small cell lung cancer (NSCLC) to identify actionable mutations such as EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, and BRAF, which help guide targeted therapy without always needing a fresh tissue sample.
How is a biopsy done for lung cancer?
Lung cancer tissue biopsies are typically done via bronchoscopy, CT-guided needle biopsy, endobronchial ultrasound (EBUS), or occasionally surgery, depending on where the tumor is located. A liquid biopsy, by contrast, only requires a peripheral blood draw and does not involve a procedure on the lung itself.
Why is a lung biopsy done? Do you need a biopsy to diagnose lung cancer?
A tissue biopsy is generally needed to diagnose lung cancer — it confirms the cancer is present, identifies the histology (such as adenocarcinoma vs squamous cell), and often provides tissue for genomic testing. Liquid biopsy does not usually replace this initial diagnostic step; its main role is profiling mutations and monitoring resistance once lung cancer is already diagnosed, particularly in advanced disease.
Liquid biopsy vs tissue biopsy for lung cancer — which is better?
Neither is universally better; they serve different purposes. Tissue biopsy confirms diagnosis and histology and is usually needed at least once. Liquid biopsy is minimally invasive and useful for mutation profiling when a repeat tissue procedure is risky, tissue is insufficient, or a fast result is needed after disease progression. A negative liquid biopsy does not always rule out a mutation, since some lung tumors shed very little ctDNA.
What does a positive lung cancer liquid biopsy result mean?
A positive result means a reportable mutation, such as EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, or BRAF, was detected in your blood sample. It identifies a molecular driver that may be matched to a targeted therapy, but it does not by itself indicate cancer stage or prognosis — that requires correlation with imaging, pathology, and your overall clinical picture, ideally with expert or tumor board input.
Can liquid biopsy detect lung cancer early, or be used for lung cancer screening?
Not reliably yet. Liquid biopsy is well established for mutation profiling in diagnosed, advanced NSCLC, but as a tool for screening or early detection in people without a diagnosis, it currently lacks sufficient sensitivity — early-stage tumors shed very little ctDNA. Research into early-detection liquid biopsy is progressing (several clinical trials are underway), but it is not yet a validated screening test. If early lung cancer detection is your goal, talk to your doctor about currently recommended screening approaches such as low-dose CT.
What is the role of liquid biopsy in lung cancer treatment?
In lung cancer, liquid biopsy is mainly used to find actionable mutations for targeted therapy selection, to detect resistance mutations (such as EGFR T790M/C797S) after progression on treatment, and to provide a molecular profile quickly when a repeat tissue biopsy is not feasible.
Which companies offer liquid biopsy tests for lung cancer in India?
Several global platforms — including Guardant360, FoundationOne Liquid CDx, Tempus xF/xF+, and Caris Assure — offer liquid biopsy testing that is accessible in India through partner labs and logistics networks. BigOHealth coordinates sample collection and lab logistics for these platforms and also independently reviews reports from any of them, helping you choose the right option for your lung cancer case rather than promoting one single lab.
Can I buy a liquid biopsy test kit for lung cancer online in India?
No. Liquid biopsy for lung cancer is not an over-the-counter or at-home test kit — it requires a clinically ordered blood draw, laboratory processing, and expert interpretation of the report by an oncologist or molecular oncology team. BigOHealth arranges testing with clinical oversight rather than selling self-administered kits.
What is the typical turnaround time for lung cancer liquid biopsy results in India?
Most lung cancer liquid biopsy reports are available within 7–14 business days after sample collection and lab receipt. Turnaround can vary by platform, courier logistics, and whether expert report interpretation is added.
Can you review my existing lung cancer liquid biopsy report?
Yes. BigOHealth can independently review existing Guardant360, FoundationOne Liquid CDx, Tempus, Caris, or hospital ctDNA reports for lung cancer. Our molecular oncology team explains actionable mutations, resistance findings, ctDNA fraction, VUS, and whether any repeat or tissue testing is needed — without requiring you to repeat the test unless clinically necessary.
Still have questions about your Liquid Biopsy for Lung Cancer report or results?
Book Lung Cancer Liquid Biopsy or Review an Existing Report
Whether you need first-time testing or a second opinion on a completed report, our molecular oncology team can help you choose the next step.
